Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Caribou Biosciences Inc (CRBU)

Caribou Biosciences Inc (CRBU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,014
  • Shares Outstanding, K 93,005
  • Annual Sales, $ 9,990 K
  • Annual Income, $ -149,110 K
  • EBIT $ -167 M
  • EBITDA $ -167 M
  • 60-Month Beta 2.36
  • Price/Sales 7.35
  • Price/Cash Flow N/A
  • Price/Book 0.28
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.65
  • Most Recent Earnings $-0.39 on 03/10/25
  • Next Earnings Date 05/06/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 432.24% ( +141.19%)
  • Historical Volatility 98.87%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 432.24% on 05/09/25
  • IV Low 8.71% on 10/14/24
  • Put/Call Vol Ratio 0.54
  • Today's Volume 86
  • Volume Avg (30-Day) 83
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 4,407
  • Open Int (30-Day) 4,374

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.40
  • Number of Estimates 3
  • High Estimate -0.35
  • Low Estimate -0.47
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7100 +9.06%
on 04/16/25
0.9378 -17.43%
on 04/11/25
-0.1212 (-13.53%)
since 04/09/25
3-Month
0.6600 +17.32%
on 04/07/25
1.4600 -46.97%
on 02/18/25
-0.5757 (-42.64%)
since 02/07/25
52-Week
0.6600 +17.32%
on 04/07/25
3.9150 -80.22%
on 05/13/24
-2.8757 (-78.79%)
since 05/09/24

Most Recent Stories

More News
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

CRBU : 0.7743 (-1.99%)
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

CRBU : 0.7743 (-1.99%)
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

CRBU : 0.7743 (-1.99%)
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CRBU : 0.7743 (-1.99%)
Caribou Biosciences to Participate in Upcoming Investor Conferences

CRBU : 0.7743 (-1.99%)
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

CRBU : 0.7743 (-1.99%)
Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

CRBU : 0.7743 (-1.99%)
Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer

CRBU : 0.7743 (-1.99%)
Caribou Biosciences to Participate in Upcoming Investor Conferences

CRBU : 0.7743 (-1.99%)
Caribou Biosciences Reports Third Quarter 2024 Financial Results and  Provides Business Update

CRBU : 0.7743 (-1.99%)

Business Summary

Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 0.9571
2nd Resistance Point 0.9116
1st Resistance Point 0.8430
Last Price 0.7743
1st Support Level 0.7289
2nd Support Level 0.6834
3rd Support Level 0.6148

See More

52-Week High 3.9150
Fibonacci 61.8% 2.6716
Fibonacci 50% 2.2875
Fibonacci 38.2% 1.9034
Last Price 0.7743
52-Week Low 0.6600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar